Skip to main content
. 2022 Feb 21;11:38. doi: 10.1038/s41377-022-00729-4

Fig. 4. Targeted PDT using HER2-specific lentiviruses (LVs) as carriers of NanoLuc-miniSOG gene.

Fig. 4

a Schematic representation of experiment. HER2-positive tumor is targeted with HER2-specific LVs carrying the NanoLuc-miniSOG gene. DARPin_9-29 incorporated in LV’s envelope targets LVs to HER2-specific tumor. b Comparison of receptor specificity and transduction efficiencies of VSV-pseudotyped and HER2-retargeted lentiviral vectors. Histograms demonstrate similar transduction efficiencies of VSV-tagRFP LVs in HER2-positive and HER2-negative cell line, whereas DARPin_9-29-tagRFP LVs were able to exclusively transduce HER2-positive BT-474 cells. c Tumor-growth curves for control group (mice treated with PBS only), as well as for groups carrying NanoLuc or NanoLuc-miniSOG LVs particles and treated with furimazine. Data are presented as the mean ± SD (n = 6). d In vivo bioimaging of animals bearing HER2-positive tumors and injected i.t. with LVs-NanoLuc-miniSOG or LVs-NanoLuc. Three mice from each group on the 13th day after LVs injection are presented